Quantitative and qualitative variations of TILs in risk stratification and patient selection for neoadjuvant chemotherapy of luminal B and triple negative breast cancer immunophenotype
Dataset: tils_in_lbbc_and_tnbc_nact.xlsx, 220.23 KB Access Condition: Closed access Description: Retrospektivno sakupljeni anonimizirani klinički podatci, iz računalne baze podataka Zavoda za patologiju - Vegasoft i iz Informatičkog bolničkog sustava - IBIS. Baza podataka koja se koristila u navedenom originalnom istraživanju uz odobrenje Etičkog povjerenstva KBC-a Rijeka (2170-29-02/1-19-2) za prikupljanje i obradu. (Croatian)
Please login to the repository to save this object to your list.
Cite this document
Avirović, M. (2025). Quantitative and qualitative variations of TILs in risk stratification and patient selection for neoadjuvant chemotherapy of luminal B and triple negative breast cancer immunophenotype [Data set]. https://urn.nsk.hr/urn:nbn:hr:184:637606.
Avirović, Manuela. Quantitative and qualitative variations of TILs in risk stratification and patient selection for neoadjuvant chemotherapy of luminal B and triple negative breast cancer immunophenotype. Medicinski fakultet, 2025. 24 Feb 2025. https://urn.nsk.hr/urn:nbn:hr:184:637606.
Avirović, Manuela. 2025. Quantitative and qualitative variations of TILs in risk stratification and patient selection for neoadjuvant chemotherapy of luminal B and triple negative breast cancer immunophenotype. Medicinski fakultet. https://urn.nsk.hr/urn:nbn:hr:184:637606.
Avirović, M. 2025. Quantitative and qualitative variations of TILs in risk stratification and patient selection for neoadjuvant chemotherapy of luminal B and triple negative breast cancer immunophenotype. Medicinski fakultet. [Online]. [Accessed 24 February 2025]. Available from: https://urn.nsk.hr/urn:nbn:hr:184:637606.
Avirović M. Quantitative and qualitative variations of TILs in risk stratification and patient selection for neoadjuvant chemotherapy of luminal B and triple negative breast cancer immunophenotype. [Internet]. Medicinski fakultet: Braće Branchetta 20, Rijeka, HR; 2025, [cited 2025 February 24] Available from: https://urn.nsk.hr/urn:nbn:hr:184:637606.
M. Avirović, Quantitative and qualitative variations of TILs in risk stratification and patient selection for neoadjuvant chemotherapy of luminal B and triple negative breast cancer immunophenotype, Medicinski fakultet, 2025. Accessed on: Feb 24, 2025. Available: https://urn.nsk.hr/urn:nbn:hr:184:637606.
Quantitative and qualitative variations of TILs in risk stratification and patient selection for neoadjuvant chemotherapy of luminal B and triple negative breast cancer immunophenotype
Ana Car Peterko (Other) KBC Rijeka; Medicinski fakultet Sveučilište u Rijeci
Scientific / art field, discipline and subdiscipline
BIOMEDICINE AND HEALTHCARE Clinical Medical Sciences Pathology
Abstract (english)
Luminal B breast cancer (LBBC) represents an aggressive, high-grade ER+ disease, associated with a high proliferation rate of tumor cells, higher mutation burden and higher probability of eliciting the immune response. Clinical and pathological data from 89 patients of stage II-III, triple-negative(TN) and luminal B-like BC(LB-like BC) were included in the analysis. All patients were submitted to neoadjuvant chemotherapy (NACT). Quantitative and qualitative evaluation of TILs was performed on tissue microarrays constructed from pretreatment core-needle biopsy tumor specimens. The proportion of stromal TILs, CD8, CD4 and PD-L1 positive(+) immune cells (IC), as well as the number of FOXP3, CTLA4 and HSP-70+IC was observed concerning tumor immunophenotype, traditional clinicopathological prognostic factors and tumor response to NACT. There was no statistically significant difference in the proportion of stromal TILs between LB-like and TNBC (P=0.344) cohorts. However, a higher CD4/CD8 ratio was associated with the TNBC biology (P=0.018) and within the LB-like BC cohort with high proliferation index and metastatic nodal involvement (P=0.045, P=0.015). Within the LB-like BC cohort, a higher expression of PD-L1 and HSP70+IC was associated with high proliferation index of tumor cells (P=0.018, P=0.040), massive metastatic nodal involvement (P=0.002, P=0.026) and higher stages of disease (P=0.004, P=0.042). Better response to NACT was associated with higher number of HSP70+IC and a higher proportion of CD8+ cells within LB-like BC cohort (P=0.045, P=0.012). Routine evaluation of immune markers and HSP70 may help identify high-risk patients of LB-like breast cancer who would have a better response to NACT.
Methods (croatian)
Nakon što se pregledom informatičkih baza podataka, Vegasoft i IBIS, pronađu slučajevi prema uključnim kriterijima istraživanja, sirovi podaci se pohranjuju na odvojenu i zaštićenu lokaciju od lokacije radnih verzija istraživačkih podataka. Podaci će se obraditi i pripremiti za statističku analizu.
Number: uniri-biomed-18-259 1428 Title (croatian): Predictive and prognostic role of immune system cells, PD-1, PDL-1 and heat shock proteins in patients with triple negative, HER-2 positive and neoadjuvant treated breast cancer Acronym: uniri-biomed-18-259 1428 Leader: Manuela Avirović